PARIS, FRANCE, February 12, 2024 – Qynapse had the pleasure of participating in “Challenges of AI in Healthcare”, an event organized by PariSanté Campus and French Healthcare Association as part of the AI Action Summit in Paris.
This gathering brought together key stakeholders from academia and industry to discuss the opportunities and challenges of integrating AI into healthcare systems. It was an inspiring moment to witness how the ecosystem is mobilizing to advance responsible and high-impact use of artificial intelligence in health.
We welcome the announcement of a national roadmap on AI in health, a critical step in ensuring ethical, secure, and impactful AI-driven innovations.
About Qynapse: Qynapse SAS is a medical technology company commercializing an AI-powered and proprietary neuroimaging software platform, creating the potential for earlier clinical precision on the frontlines of CNS disease. Qynapse’s flagship solution, QyScore®, FDA-Cleared and CE-Marked, adds the potential for more precise and objective brain scan analysis. Qynapse is headquartered in France with offices in the US Canada.
www.qynapse.com